OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer


In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

As part of its OncView™ program, CancerNetwork hosted a discussion Lori Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital in Boston, who shared her perspective on updates in the treatment of second-line radioiodine-refractory differentiated thyroid cancer, or DTC.

In the video series, some of the content discussed included:

To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Related Content